<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/79789">
      <dc:title>Beneficial Effects of Limosilactobacillus fermentum in the DCA Experimental Model of Irritable Bowel Syndrome in Rats</dc:title>
      <dc:creator>Rodríguez Sojo, María Jesús</dc:creator>
      <dc:creator>García García, Jorge</dc:creator>
      <dc:creator>Ruiz Malagón, Antonio Jesús</dc:creator>
      <dc:creator>Díez Echave, Patricia</dc:creator>
      <dc:creator>Hidalgo García, Laura</dc:creator>
      <dc:creator>Molina Tijeras, José Alberto</dc:creator>
      <dc:creator>González Lozano, Elena</dc:creator>
      <dc:creator>López Escánez, Laura</dc:creator>
      <dc:creator>Rodríguez Cabezas, María Elena</dc:creator>
      <dc:creator>Rodríguez Sánchez, María José</dc:creator>
      <dc:creator>Rodríguez Nogales, Alba</dc:creator>
      <dc:creator>Mediavilla García, Palmira Cristina</dc:creator>
      <dc:creator>Gálvez Peralta, Julio Juan</dc:creator>
      <dc:subject>IBS rat model</dc:subject>
      <dc:subject>Probiotic</dc:subject>
      <dc:subject>Limosilactobacillus fermentum CECT5716</dc:subject>
      <dc:subject>Intestine anti-inflammatory activity</dc:subject>
      <dc:subject>Visceral analgesia</dc:subject>
      <dc:description>Limosilactobacillus fermentum CECT5716, a probiotic strain isolated from human milk, has&#xd;
reported beneficial effects on different gastrointestinal disorders. Moreover, it has shown its ability to&#xd;
restore altered immune responses, in association with microbiome modulation in different pathological&#xd;
conditions. Therefore, our aim was to assess the effects of a Limosilacbacillus fermentum CECT5716&#xd;
in a rat experimental model of irritable bowel syndrome (IBS) that resembles human IBS. The experimental&#xd;
IBS was induced by deoxycholic acid (DCA) in rats and then, Limosilactobacillus fermentum&#xd;
CECT5716 (109 CFU/day/rat) was administered. Behavioral studies, hyperalgesia and intestinal&#xd;
hypersensitivity determinations were performed and the impact of the probiotic on the inflammatory&#xd;
and intestinal barrier integrity was evaluated. Additionally, the gut microbiota composition was&#xd;
analyzed. Limosilactobacillus fermentum CECT5716 attenuated the anxiety-like behavior as well as the&#xd;
visceral hypersensitivity and referred pain. Moreover, this probiotic ameliorated the gut inflammatory&#xd;
status, re-establishing the altered intestinal permeability, reducing the mast cell degranulation and&#xd;
re-establishing the gut dysbiosis in experimental IBS. Therefore, our results suggest a potential use of&#xd;
Limosilactobacillus fermentum CECT5716 in clinical practice for the management of IBS patients.</dc:description>
      <dc:date>2023-02-09T11:40:21Z</dc:date>
      <dc:date>2023-02-09T11:40:21Z</dc:date>
      <dc:date>2022-12-21</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Rodríguez-Sojo, M.J... [et al.]. Beneficial Effects of Limosilactobacillus fermentum in the DCA Experimental Model of Irritable Bowel Syndrome in Rats. Nutrients 2023, 15, 24. [https://doi.org/10.3390/nu15010024]</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10481/79789</dc:identifier>
      <dc:identifier>10.3390/nu15010024</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución 4.0 Internacional</dc:rights>
      <dc:publisher>MDPI</dc:publisher>
   </ow:Publication>
</rdf:RDF>